+、CD4+、CD4+/CD8+水平升高,CD8+水平降低(P<0.05),其中觀察組CD3+、CD4+、CD4+/CD8+水平高于對照組,CD8+水平低于對照組,差異有統(tǒng)計學(xué)意義(P<0.05)。治療后,兩組腸道內(nèi)雙歧桿菌、乳酸桿菌水平升高,葡萄球菌、大腸桿菌水平降低(P<0.05);其中觀察組雙歧桿菌、乳酸桿菌水平高于對照組,葡萄球菌、大腸桿菌水平低于對照組,差異有統(tǒng)計學(xué)意義(P<0.05)。治療后,兩組排便次數(shù)、排便難度、排便時間和大便性狀等評分均降低(P<0.05);其中觀察組排便次數(shù)、排便難度、排便時間和大便性狀評分低于對照組,差異有統(tǒng)計學(xué)意義(P<0.05)。治療后,兩組中醫(yī)癥候總分明顯減少,HRQOL評分升高(P<0.05),其中觀察組中醫(yī)癥候總分低于對照組,HRQOL評分高于對照組,差異有統(tǒng)計學(xué)意義(P<0.05)。兩組不良反應(yīng)發(fā)生率無明顯差異。結(jié)論 槐杞黃顆粒聯(lián)合聚乙二醇4000散治療便秘患兒,能夠顯著改善患兒便秘癥狀和生存質(zhì)量,提高免疫功能,調(diào)節(jié)腸道內(nèi)菌群水平,效果顯著。;Objective To study the therapeutic effect of Huaiqihuang Granules combined with Macrogol 4 000 Powder on constipation, intestinal flora, and immune function in children. Methods A total of 96 children with constipation admitted to Xingtai People's Hospital fromApril 2016 to February 2019 were randomly divided into control group and observation group, and each group had 48 cases. In the control group, children were po administered with Macrogol 4000 Powder in warm water for twice, 1.5 g/(kg·d), and the amount was gradually reduced according to the fecal impaction of the children. In the observation group, the children were po administered with Huaiqihuang Granules with warm water on the basis of the control group, 10 g/time, and twice daily. 2 weeks for a course of treatment, children were treated for two courses of treatment. The clinical efficacy in two groups was observed, and the immune function, intestinal flora level, clinical symptom score, total TCM syndrome score, HRQOL score, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the total effective rate in the control group was 79.17%, which was lower than 93.75% in the observation group, the difference was statistically significant (P<0.05). After treatment, the levels of CD3+, CD4+, CD4+/CD8+ in two groups were increased, and the levels of CD8+ were decreased (P<0.05). And the levels of CD3+, CD4+, and CD4+/CD8+ in the observation group were significantly higher than those in the control group (P<0.05), the level of CD8+ was lower than those in the control group, the difference was statistically significant (P<0.05). After treatment, the levels of bifidobacteria and lactobacillus in the intestines of two groups were increased, while the levels of staphylococcus and escherichia coli were decreased (P<0.05). And the levels of bifidobacteria and lactobacillus in the observation group were higher than those in the control group, the levels of staphylococcus and escherichia coli were lower than those in the control group, with statistically significant differences (P<0.05). After treatment, the score of defecation frequency, defecation difficulty, defecation time, and defecation character in two groups were all decreased (P<0.05). And the defecation frequency, defecation difficulty, defecation time and stool character score in the observation group were lower than those in the control group, with statistically significant differences (P<0.05). After treatment, the total score of TCM syndromes in two groups were significantly decreased, and the HRQOL score were increased (P<0.05). And the total score of TCM syndromes in the observation group was lower than that in the control group, while the HRQOL score was higher than that in the control group, with statistically significant differences (P<0.05). There was no significant difference in the incidence of adverse reactions between two groups. Conclusion Huaiqihuang Granules combined with Macrogol 4000 Powder can significantly improve the constipation symptoms and quality of life of children with constipation, improve the immune function, and regulate the level of intestinal flora, the effect is significant."/>

醉酒后少妇被疯狂内射视频,一本色道久久综合一,在线天堂新版资源www在线下载,中文字幕乱人伦高清视频,中字幕视频在线永久在线观看免费

首頁 > 過刊瀏覽>2020年第43卷第4期 >2020,43(4):729-733. DOI:10.7501/j.issn.1674-6376.2020.04.026
上一篇 | 下一篇

槐杞黃顆粒聯(lián)合聚乙二醇4000散治療兒童便秘療效及對患兒腸道菌群、免疫功能的影響

Effect of Huaiqihuang Granules combined with Macrogol 4000 Powder on constipation, intestinal flora, and immune function in children

發(fā)布日期:2020-04-10
您是第位訪問者
藥物評價研究 ® 2025 版權(quán)所有
技術(shù)支持:北京勤云科技發(fā)展有限公司
津備案:津ICP備13000267號 互聯(lián)網(wǎng)藥品信息服務(wù)資格證書編號:(津)-非經(jīng)營性-2015-0031